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Summary
Background Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports 
of treatment failure. We did a systematic review and meta-analysis to investigate the effect of chloroquine dose and 
the addition of primaquine on the risk of recurrent vivax malaria across different settings.
Methods A systematic review done in MEDLINE, Web of Science, Embase, and Cochrane Database of Systematic 
Reviews identified P vivax clinical trials published between Jan 1, 2000, and March 22, 2017. Principal investigators 
were invited to share individual patient data, which were pooled using standardised methods. Cox regression analyses 
with random effects for study site were used to investigate the roles of chloroquine dose and primaquine use on rate 
of recurrence between day 7 and day 42 (primary outcome). The review protocol is registered in PROSPERO, number 
CRD42016053310.
Findings Of 134 identified chloroquine studies, 37 studies (from 17 countries) and 5240 patients were included. 
2990 patients were treated with chloroquine alone, of whom 1041 (34·8%) received a dose below the target 25 mg/kg. 
The risk of recurrence was 32·4% (95% CI 29·8–35·1) by day 42. After controlling for confounders, a 5 mg/kg higher 
chloroquine dose reduced the rate of recurrence overall (adjusted hazard ratio [AHR] 0·82, 95% CI 0·69–0·97; 
p=0·021) and in children younger than 5 years (0·59, 0·41–0·86; p=0·0058). Adding primaquine reduced the risk of 
recurrence to 4·9% (95% CI 3·1–7·7) by day 42, which is lower than with chloroquine alone (AHR 0·10, 0·05–0·17; 
p<0·0001).
Interpretation Chloroquine is commonly under-dosed in the treatment of vivax malaria. Increasing the recommended 
dose to 30 mg/kg in children younger than 5 years could reduce substantially the risk of early recurrence when 
primaquine is not given. Radical cure with primaquine was highly effective in preventing early recurrence and may 
also improve blood schizontocidal efficacy against chloroquine-resistant P vivax.
Funding Wellcome Trust, Australian National Health and Medical Research Council, and Bill & Melinda Gates 
Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Chloroquine has been the mainstay of treatment for 
Plasmodium vivax for over 60 years.1,2 The first 
observations of chloroquine-resistant P vivax were 
published in 1989,3,4 and over the subsequent two decades 
several reports suggested that chloroquine-resistant 
P vivax was present in most vivax-endemic countries.5 
Suboptimal treatment results in recurrent parasitaemia, 
from both recrudescent infections and relapses arising 
from reactivation of the dormant liver stages. Recurrent 
parasitaemia is associated with a cumulative risk 
of severe anaemia, increased mortality, and greater 
transmission potential.6–8
Treatment options for chloroquine-resistant P vivax 
include optimising chloroquine regimens or changing 
policy to a more effective blood schizontocidal agent. In 
countries where high-grade chloroquine-resistant P vivax 
is prevalent, national treatment guidelines have been 
revised to a universal policy of artemisinin combination 
therapy (ACT) for all species of malaria.5,9 Where 
chloroquine remains the first-line treatment of P vivax, the 
treatment regimen can potentially be optimised, either by 
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increasing the dose or duration of chloroquine, or by 
combining chloroquine with an additional drug with blood 
schizontocidal activity or the ability to reverse chloroquine 
resistance.10 Although early dose-finding studies showed 
excellent efficacy against P vivax at doses below 25 mg/kg, 
higher doses are well tolerated and might provide increased 
efficacy.2,11 Alternatively, the addition of a hypnozoitocidal 
agent such as primaquine to chloroquine improves blood 
schizontocidal efficacy and reduces relapse.12,13
To explore alternative strategies for improving 
chloroquine efficacy, we did a pooled analysis of 
individual patient data from prospective P vivax clinical 
trials to investigate the effect of chloroquine dose and 
primaquine co-administration on the risks of P vivax 
recurrence between day 7 and day 42.
Methods
Search strategy and selection criteria
We searched MEDLINE, Web of Science, Embase, and 
Cochrane Database of Systematic Reviews, according to 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses statement (appendix pp 2–5). 
Prospective therapeutic efficacy trials of uncomplicated 
P vivax malaria published in any language between 
Jan  1, 1960, and March 22, 2017, were identified using 
the following search terms: (malaria OR plasmo dium) 
AND (amodiaquine OR atovaquone OR artemisinin OR 
arteether OR artesunate OR artemether OR artemotil 
OR azithromycin OR artekin OR chloroquine OR chlor- 
proguanil OR cycloguanil OR clindamycin OR coartem 
OR dapsone OR dihydro artemisinin OR duo-cotecxin 
OR doxycycline OR halofan trine OR lumefantrine OR 
lariam OR malarone OR mefloquine OR naphthoquine 
OR naphthoquinone OR piperaquine OR primaquine 
OR proguanil OR pyrimethamine OR pyronaridine OR 
quinidine OR quinine OR riamet OR sulpha doxine OR 
tetracycline OR tafenoquine). Further details are 
provided in the appendix (p 6).14
The review process was done by two independent 
investigators (RJC and RNP), who also extracted the data. 
Disagreement was resolved through discussion. To 
ensure results were relevant to the current clinical 
landscape, only studies published after 2000 were 
included. Principal investigators were contacted and 
invited to share individual patient data and any additional 
unpublished data.
Studies assessing patients with P vivax monoinfection 
treated with chloroquine alone or chloroquine plus 
primaquine during the first 28 days after treatment were 
included. Individual patient data were uploaded into the 
WorldWide Antimalarial Resistance Network (WWARN) 
secure repository, anonymised, and processed according 
to a data management plan.15
All data included in this analysis were obtained in 
accordance with ethical approvals from the country of 
origin. The data are fully anonymised and cannot be 
traced back to identifiable individuals; these do not 
require review from an ethics committee according to 
the guidelines of the Oxford Central University Research 
Ethics Committee.
Procedures
Chloroquine and primaquine doses were calculated from 
the number of tablets given to each patient. If these data 
were unavailable, doses were calculated based on the study 
protocol and assuming complete adherence. Individual 
patient records were excluded if the course of chloroquine 
was incomplete, the course of chloroquine or primaquine 
was intermittent, or if information on dose, parasitaemia, 
age, or weight were unavailable. Early primaquine was 
defined as the first dose of primaquine administered in the 
first 3 days of treatment (ie, before day 3).
Parasite prevalence at each study site was categorised 
as low (P vivax parasite rate <1·5%), moderate (≥1·5% and 
<4·0%), or high (≥4·0%) based on transmission 
estimates obtained from the Malaria Atlas Project and 
Research in context
Evidence before this study
Using the search terms “vivax” and “chloroquine”, MEDLINE, 
Web of Science, Embase, and the Cochrane Database of 
Systematic Reviews were searched for articles published before 
Nov 29, 2017, that assessed the efficacy of chloroquine, with or 
without primaquine, for uncomplicated Plasmodium vivax 
malaria. A systematic review and meta-analysis showed that 
there was evidence of reduced chloroquine efficacy for P vivax 
present in most P vivax endemic countries. No reviews or 
pooled analyses had assessed the effect of chloroquine dose on 
the risk of recurrence.
Added value of this study
Our pooled analysis of individual patient data from 37 studies 
across 17 countries is, to our knowledge, the largest individual 
pooled analysis of P vivax clinical trials so far. Our findings 
highlight the substantial benefit of increasing the dose of 
chloroquine in children younger than 5 years and the additional 
benefit of adding primaquine to chloroquine.
Implications of all the available evidence
Chloroquine is currently under-dosed in children younger than 
5 years. Increasing the target dose of chloroquine from 
25 mg/kg to 30 mg/kg could significantly reduce the risk of 
P vivax recurrence within 42 days in children younger than 
5 years who are not given primaquine. The risk of P vivax 
recurrence was reduced by an even greater degree by the 
addition of primaquine to chloroquine in all age groups, 
through prevention of relapse and probably improvement in 
blood schizontocidal efficacy. These measures warrant 
consideration by regional and global policy makers to reduce 
the risk of early P vivax recurrence.
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observed study site reinfection rates (appendix pp 16–17).16 
Study sites were also categorised as having long or short 
P vivax relapse periodicity according to geographical 
location.17 Regions with short relapse periodicity were 
defined as having a median time to patent relapse of 
47 days or fewer.17
Outcomes
The primary outcome was the risk of P vivax recurrence 
between day 7 and day 42. Secondary outcomes were the 
risk of recurrence between day 7 and day 28 and early 
parasitological clearance, defined as the prevalence of 
parasitaemia on days 1, 2, and 3.15
Statistical analysis
The risk of recurrence was calculated using Kaplan-
Meier survival analyses. Patients were right censored at 
the day of their first recurrence, the day they were last 
seen, the day before a more than 18-day blood smear gap, 
or day 42, depending on which came first.15
Cox’s proportional hazards regression was used to 
estimate the association between chloroquine dose 
and co-administration of primaquine with the rate of 
recurrence, adjusting for the potential confounders of 
age, sex, baseline parasitaemia, and regional relapse 
periodicity, and applying shared frailty for study sites to 
account for additional variation related to different sites. 
A linear association between chloroquine dose and the 
log rate of recurrence was checked visually, and 
the  proportional hazards assumption tested using 
Schoenfeld residuals. If non-proportional hazards were 
present, interactions between terms and time were 
assessed. Owing to collinearity with relapse periodicity, 
geographical region and parasite prevalence were not 
included. Age was categorised into three groups 
(<5 years, 5 to <15 years, and ≥15 years) when a linear 
association with outcome was not present. Figures of 
risk of recurrence were estimated according to 
chloroquine dose and primaquine co-administration, 
adjusted for other confounders and assuming no study 
site effect.
The associations between chloroquine dose and 
microscopy-detectable parasite positivity in patients 
treated with chloroquine alone were analysed by logistic 
regression, with study sites included as a random effect. 
The association between the first day of parasite clearance 
and parasitaemia recurrence between day 7 and day 28 
was assessed by Cox’s proportional hazards regression.
Heterogeneity of studies was assessed by removal of 
one study site at a time and calculation of the coefficient 
of variation around parameter estimates. Additionally, 
baseline characteristics of included studies were 
compared with targeted studies that were not included.
Statistical analyses were done in Stata (version 15.0) 
and R (version 3.4.0), according to an a-priori statistical 
analysis plan.18 The review protocol is registered in 
PROSPERO, number CRD42016053310.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. RNP had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
232 published P vivax clinical trials were identified, 
134 of which included patients treated with chloroquine 
and were published between Jan 1, 2000, and 
March 22, 2017 (figure 1). Individual patient data were 
Figure 1: Study profile
*Additional patient data available from published studies that were not described in the published enrolment 
cohorts.
232 studies from literature review of all published 
 clinical trials of Plasmodium vivax
64 studies published before 2000
168 studies published since 2000 (n=36 515)
34 studies excluded
 28 studies without chloroquine 
 4 studies in which adjunctive drugs were used
 2 studies of pregnant women
134 studies with chloroquine targeted for pooled 
 analysis (n=30 656)
101 studies excluded
 8 studies with no data available 
 15 studies with investigators unable to be
               contacted
 7 studies without minimum data for inclusion
 7 studies with initial response but no data
               given
 64 studies with no response from investigators
33 studies available for inclusion (n=6491; 
 21·2% of targeted sample size)
3148 patients excluded
 2815 not treated with chloroquine
 59 with adjunctive drugs
 5 with no P vivax at enrolment
 78 missing body weight, age, sex, or 
 dosing variable
 27 with incomplete schizontocidal
 treatment
 17 with mixed infection
 147 with intermittent dosing
5240 patients (37 studies) included in the analysis
 2990 with chloroquine alone before day 42
 1790 with chloroquine and primaquine 
 before day 3
 460 with primaquine between day 3 and day 28
1897 additional patients included
 1780 from four unpublished studies
 117 from published studies*
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available from 33 published studies19–51 including 
6491 patients (21·2%) of the target sample size of 30 656. 
Additionally, patient data from four unpublished studies 
including 1780  patients and an additional 117 patients 
related to patient cohorts from the published studies, but 
not described in the manuscripts, were available (figure 1; 
appendix pp 7–9, 13–15). 5573 (66·4%) of 8388 patients 
from these studies were treated with chloroquine, of 
whom 333 (6·0%) were excluded because of protocol 
violations. Of the 5240 patients included in the analysis, 
2990 (57·1%) were treated with chloroquine alone, 
1790 (34·2%) were treated with chloroquine plus early 
primaquine commencing before day 3, and 460 (8·8%) 
received primaquine after day 3. Patients were followed 
up for 28 days in 20 studies (n=3041), 29–42 days in seven 
studies (n=675), 43–63 days in four studies (n=583), and 
more than 63 days in six studies (n=941). Mg/kg dosing 
was calculated from the number of tablets given for 
3197 (61·0%) of 5240 patients, with the remainder 
extrapolated from the protocol, assuming complete 
adherence.
The median age of patients was 20 years (IQR 10–31; 
range 3 months to 88 years), with 450 (8·6%) aged 
younger than 5 years (table 1). 3773 (72·0%) patients were 
from the Asia-Pacific region, compared with 776 (14·8%) 
from the Americas and 691 (13·2%) from Africa. 
2187 (41·7%) patients came from areas of short relapse 
periodicity. Patients treated with chloroquine alone were 
younger and more likely to come from regions of long 
relapse periodicity, have higher baseline parasitaemia, 
present with anaemia (haemoglobin <10 g/dL), and come 
from Africa rather than the Americas (table 1). The 
corresponding proportions of patients from studies 
targeted for inclusion, but not included in the pooled 
analysis, were similar (appendix pp 18–21).
In the 2990 patients from 26 studies treated with 
chloroquine alone, the median total dose of chloroquine 
was 25·4 mg/kg (IQR 24·2–28·1; range 6·8–75·0) with 
1041 patients (34·8%) receiving less than the WHO 
recommended target dose of chloroquine of 25 mg/kg 
(appendix pp 10, 22). This proportion increased with 
weight, age, male sex, and regions of short relapse 
periodicity (appendix pp 11, 22). Under-dosing in children 
younger than 5 years was similar between those dosed 
with chloroquine syrup or a liquid mixture from crushed 
tablets (11 [17%] of 66) and those dosed with divided 
tablets (39 [13%] of 293; p=0·48).
Information on acute vomiting was available in eight 
studies (n=557), with 20 (4%) of 557 patients vomiting at 
least one dose of chloroquine within 60 min of 
administration. After adjusting for age, sex, baseline 
parasitaemia, presence of baseline fever, and relapse 
periodicity, chloroquine dose was not a significant risk 
factor for vomiting (adjusted odds ratio [AOR] 1·14, 
95% CI 0·96–1·34; p=0·13; appendix p 24).
505 patients treated with chloroquine alone had 
recurrent parasitaemia between day 7 and day 42. In 
patients followed up for 42 days, 69 (23%) of 
298 recurrences within this period occurred by day 28. 
The cumulative risk of recurrence was 10·4% (95% CI 
9·3–11·6) at day 28 and 32·4% (29·8–35·1) at day 42. The 
risks of recurrence for individual studies are presented in 
the appendix (p 12).
After controlling for age, parasitaemia, regional relapse 
periodicity, and sex, a 5 mg/kg increase in chloroquine 
dose reduced the rate of recurrence between day 7 and 
day 42 (adjusted hazard ratio [AHR] for every 5 mg/kg 
dose increase 0·82, 95% CI 0·69–0·97; p=0·021; table 2). 
After stratifying the model by geographical region, the 
AHR for a 5 mg/kg increase in chloroquine dose was 
Chloroquine alone 
(n=2990)
Chloroquine and 
early primaquine 
(n=1790)
Overall (n=5240)*
Sex
Female 1104 (36·9%) 571 (31·9%) 1786 (34·1%)
Male 1886 (63·1%) 1219 (68·1%) 3454 (65·9%)
Age (years)
Median (IQR) 17·0 (8·0–28·0) 23·5 (13·0–36·0) 20·0 (10·0–31·0)
<5 359 (12·0%) 88 (4·9%) 450 (8·6%)
5 to <15 916 (30·6%) 413 (23·1%) 1403 (26·8%)
≥15 1715 (57·4%) 1289 (72·0%) 3387 (64·6%)
Weight (kg)
Median (IQR) 45·0 (20·0–56·0) 51·0 (36·0–62·0) 48·0 (25·0–58·0)
5 to <15 342 (11·4%) 101 (5·6%) 445 (8·5%)
15 to <25 574 (19·2%) 208 (11·6%) 813 (15·5%)
25 to <35 235 (7·9%) 120 (6·7%) 388 (7·4%)
35 to <45 320 (10·7%) 185 (10·3%) 564 (10·8%)
45 to <55 649 (21·7%) 413 (23·1%) 1250 (23·9%)
55 to <80 777 (26·0%) 656 (36·6%) 1577 (30·1%)
≥80 93 (3·1%) 107 (6·0%) 203 (3·9%)
Relapse periodicity
Long 1914 (64·0%) 902 (50·4%) 3053 (58·3%)
Short 1076 (36·0%) 888 (49·6%) 2187 (41·7%)
Geographical region
Asia-Pacific 2112 (70·6%) 1203 (67·2%) 3773 (72·0%)
The Americas 289 (9·7%) 487 (27·2%) 776 (14·8%)
Africa 589 (19·7%) 100 (5·6%) 691 (13·2%)
Prevalence of Plasmodium vivax
Low 1243 (41·6%) 195 (10·9%) 1459 (27·8%)
Moderate 607 (20·3%) 744 (41·6%) 1723 (32·9%)
High 1140 (38·1%) 851 (47·5%) 2058 (39·3%)
Enrolment clinical variables
Parasitaemia, parasites per µL 4000 (1480–8290) 3000 (1000–7520) 3809 (1380–8360)
Haemoglobin, g/dL† 12·2 (2·1) 12·7 (2·1) 12·4 (2·1)
Anaemia, haemoglobin <10 g/dL 263/1991 (13·2%) 138/1605 (8·6%) 428/3840 (11·1%)
Gametocytes present 1473/1642 (89·7%) 850/916 (92·8%) 2502/2763 (90·6%)
Fever, temperature >37·5°C 1280/2757 (46·4%) 687/1546 (44·4%) 2267/4752 (47·7%)
Data are number (%), median (IQR), mean (SD), or n/N (%). Some percentages do not add up to 100 because of 
rounding. *Includes 460 patients treated with chloroquine and primaquine who started primaquine after the first 
3 days; †Data not available for 1400 of 5240 patients: 999 in the chloroquine alone group and 185 in the chloroquine 
and primaquine group. 
Table 1: Demographics and baseline characteristics
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0·75 (95% CI 0·59–0·96; p=0·022) in the Asia-Pacific, 
0·84 (0·59–1·20; p=0·35) in the Americas, and 0·95 
(0·72–1·25; p=0·72) in Africa. Age, baseline parasitaemia, 
and short regional relapse periodicity were also associated 
with parasite recurrence between day 7 and day 42 
(table 2). The effect of dose was greatest in children aged 
younger than 5 years (AHR for every 5 mg/kg increase in 
dose 0·59, 95% CI 0·41–0·86; p=0·0058; figure 2; 
appendix p 25). Since the proportional hazards 
assumption did not hold for chloroquine dose in patients 
aged 5 years or older, variation of chloroquine dose 
hazard ratio with time was assessed. For these age groups 
(5 to <15 years and ≥15 years), the AHR of chloroquine 
dose varied with time, with chloroquine dose associated 
with a reduced rate of recurrence from day 22 to day 42 
(5 to <15 years  AHR 0·66, 95% CI 0·45–0·96; p=0·030 
and ≥15 years 0·83, 0·61–1·15; p=0·27), but there was no 
reduction with dose up to day 21 (appendix p 25). 
Sensitivity analyses in which one study site was removed 
at a time revealed no apparent bias relating to individual 
study sites from included studies (appendix pp 33–36).
Within 24 h of starting treatment, 1169 (56·5%) of 
2070 patients had cleared their detectable parasitaemia, 
increasing to 2095 (80·9%) of 2590 on day 2 and 
2369 (94·8%) of 2499 on day 3. Low chloroquine dose 
(<25 mg/kg) was a risk factor for parasitaemia on day 1 in 
the univariable analysis (odds ratio 2·09, 95% CI 1·24–3·51; 
p=0·0056), as were male sex, older age, and higher baseline 
parasitaemia (appendix p 26). After controlling for con- 
founding factors, the association between low chloroquine 
Number of 
patients
Number with 
recurrence by 
day 42
Univariable analyses Multivariable analyses*
Crude HR (95% CI) p value Adjusted HR (95% CI) p value
Chloroquine dose, every 5 mg/kg 
increase
2990 505 0·95 (0·80–1·12) 0·53 0·82 (0·69–0·97) 0·021
Age, every 1-year increase 2990 505 0·97 (0·96–0·97) <0·0001 0·96 (0·96–0·97) <0·0001
Age category, years
≥15 1715 223 Reference .. .. ..
<5 359 100 2·53 (1·94–3·30) <0·0001 .. ..
5 to <15 916 182 1·89 (1·52–2·35) <0·0001 .. ..
Weight, every 5 kg increase 990 2505 0·90 (0·88–0·93) <0·0001 .. ..
Sex
Male 1886 316 Reference .. Reference ..
Female 1104 189 0·94 (0·78–1·13) 0·50 0·96 (0·80–1·16) 0·69
Enrolment clinical variables
Parasitaemia, parasites per µL every 
ten-times increase
2990 505 1·29 (1·10–1·53) 0·0023 1·27 (1·07–1·49) 0·0049
Haemoglobin, every 1 g/dL increase 1991 352 0·87 (0·83–0·92) <0·0001 .. ..
Anaemia, haemoglobin <10 g/dL 1991 352 1·75 (1·31–2·35) 0·0002 .. ..
Fever, temperature >37·5°C 2757 478 1·27 (1·05–1·53) 0·015 .. ..
Gametocytes present 1642 335 0·98 (0·67–1·44) 0·92 .. ..
Relapse periodicity
Long 1914 144 Reference .. Reference ..
Short 1076 361 18·16 (7·47–44·19) <0·0001 21·61 (8·69–53·76) <0·0001
Region
Asia-Pacific 2112 374 Reference .. .. ..
Africa 589 76 0·14 (0·04–0·53) 0·0037 .. ..
The Americas 289 55 0·20 (0·02–2·22) 0·19 .. ..
Prevalence
Low 1243 131 Reference .. .. ..
Moderate 607 55 0·98 (0·24–4·00) 0·98 .. ..
High 1140 319 2·21 (0·46–10·62) 0·32 .. ..
Dose calculation method
Per protocol 1223 215 Reference .. .. ..
Tablet counts 1767 290 1·26 (0·31–5·11) 0·75 .. ..
Weight was excluded owing to collinearity with age. Region and P vivax prevalence were excluded owing to collinearity with regional periodicity. HR=hazard ratio. 
*The assumption of proportional hazards held for the overall model (p=0·06 for global test), with a p value of 0·007 specifically for chloroquine dose. 
Table 2: Risk factors for Plasmodium vivax recurrence between day 7 and day 42 in patients treated with chloroquine alone
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dose and parasitaemia on day 1 was attenuated (AOR 1·65, 
95% CI 0·98–2·78; p=0·060; appendix p 26). There was no 
relationship between chloroquine dose and parasite 
clearance on day 2 (AOR 1·52, 95% CI 0·78–2·97; p=0·22) 
or day 3 (1·39, 0·60–3·22; p=0·44).
In patients treated with chloroquine alone who were 
assessed at day 28, 32 (23%) of 139 who were parasitaemic 
on day 3 had recurrent P vivax between day 7 and day 28, 
compared with 229 (9%) of 2657 who had already cleared 
their parasitaemia (p<0·0001). After controlling for 
confounding factors, parasite clearance on or after day 3 
was associated with an increased rate of recurrence 
between day 7 and day 28 compared with parasite 
clearance on day 1 (AHR 3·57, 95% CI 2·09–6·11; 
p<0·0001; appendix p 27). The higher rate of recurrence 
with delayed parasite clearance was more apparent in 
studies from short periodicity regions (figure 3).
In 17 studies, 1790 patients were treated with 
chloroquine and early primaquine. 917 (51·2%) patients 
from 11 of these studies had a target dose of primaquine 
between 3·5 mg/kg and less than 5·0 mg/kg, and 
873 (48·8%) from six studies had a target dose of at least 
5·0 mg/kg. Overall, patients were administered a median 
dose of primaquine of 4·7 mg/kg (IQR 3·4–6·7; range 
0·3–13·1; appendix pp 10, 23). 1046 (58·4%) of 
1790 primaquine regimens were 14 days long (range 
7–14 days; appendix p 28).
31 patients had recurrent parasitaemia by day 42, with a 
cumulative risk of 1·4% (95% CI 0·9–2·1) at day 28 and 
4·9% (3·1–7·7) at day 42. When patients treated with 
chloroquine plus early primaquine were added to the 
previous Cox regression model, the addition of early 
primaquine was associated with a reduction in the rate of 
recurrent parasitaemia (AHR 0·10, 95% CI 0·05–0·17; 
p<0·0001; figure 4; appendix p 29). This reduction did not 
vary significantly with time; early primaquine was 
associated with a reduced rate of recurrence up to day 21 
(AHR 0·07, 95% CI 0·03–0·18; p<0·0001) and between 
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Figure 2: Risk of recurrence in patients younger than 5 years receiving 
chloroquine alone with (A) varied chloroquine doses, and in (B) long 
periodicity and (C) short periodicity regions
Dashed lines are the 95% CIs. Adjusted for age, sex, and baseline parasitaemia. 
Assumes zero effect from study site. p values are derived from a Cox model. 
Figure 3: Risk of recurrence according to day of parasite clearance in patients 
receiving chloroquine alone in (A) long and (B) short periodicity regions
Dashed lines are the 95% CIs. Adjusted for age, sex, baseline parasitaemia, and 
chloroquine dose. Assumes zero effect from study site. p values are derived from 
a Cox model.
0
Ri
sk
 o
f r
ec
ur
re
nc
e 
(%
)
10
20
30
40
50 Cleared day 1
Cleared day 2
Cleared day 3 or after
A
Day 2 vs day 1 p=0·18
Day 3 vs day 1 p<0·0001
0 7
0
Ri
sk
 o
f r
ec
ur
re
nc
e 
(%
)
Time (days)
10
14
20
30
40
50
21 28
Cleared day 1
Cleared day 2
Cleared day 3 or after
Day 2 vs day 1 p=0·18
Day 3 vs day 1 p<0·0001
B
Articles
www.thelancet.com/infection   Published online July 19, 2018   http://dx.doi.org/10.1016/S1473-3099(18)30348-7 7
day 22 and day 42 (0·10, 0·06–0·18; p<0·0001). In a 
multivariable model of patients only treated with 
chloroquine plus early primaquine, neither prima quine 
dose nor chloroquine dose were significantly associated 
with a lower rate of recurrent parasitaemia (appendix p 30).
Discussion
In this pooled analysis of individual patient data, a high 
proportion of patients, especially older males, received a 
suboptimal dose of chloroquine (<25 mg/kg); increasing 
the total mg/kg chloroquine dose reduced early 
recurrences if primaquine was not given, especially in 
children younger than 5 years; and, the risk of early 
recurrent parasitaemia was markedly reduced by 
co-administration of primaquine.
Increasing reports of declining chloroquine efficacy 
have highlighted the need for alternative treatment 
strategies for P vivax.5 In countries where there are high 
levels of chloroquine resistance, national guidelines have 
changed to ACT as first-line therapy for P vivax.52 Other 
countries have included primaquine as adjunctive 
therapy to prevent P vivax relapses, with the added 
benefit of providing additional blood schizontocidal 
activity.12,53 However, the risk of substantial haemolysis, 
coupled with poor adherence, have prevented widespread 
effective implementation.53,54 The results of this individual 
pooled data meta-analysis suggest that in the absence of 
primaquine, an increased dose of chloroquine would also 
decrease P vivax recurrence substantially in children 
younger than 5 years.
Previous pharmacokinetic studies have shown that 
chloroquine is under-dosed in children and have 
suggested that an increase in the chloroquine dose or 
dosing based on body surface area would be more 
appropriate and effective.55–58 In children younger than 
2 years, approximately twice the dose of chloroquine 
was  required to reach the same chloroquine blood 
concentration as children aged 10–14 years.55 In addition, 
Añez and colleagues58 found that children had the 
greatest variation between dose per kg of bodyweight and 
theoretical dose calculated by body surface area. 
Chloroquine blood concentrations are also lowest in 
children, in whom the risk of recurrence is greatest.58
Our data are in keeping with these findings and suggest 
that increasing the total chloroquine dose from 25 mg/kg 
to 30 mg/kg in children younger than 5 years would 
decrease the risk of early recurrence by more than 40% if 
chloroquine was used alone. Although increasing the 
target dose might reduce tolerability, substantial data 
support the safety of 30 mg/kg in children. In Guinea-
Bissau, chloroquine doses of 50 mg/kg against drug-
resistant Plasmodium falciparum were well tolerated in 
children younger than 15 years.59–62 Even higher doses 
have been used for amoebic liver abscess (21 mg/kg daily 
for 3 weeks)63 and Giardia lamblia (10 mg/kg twice daily 
for 5 days).64 Our pooled analysis did not include a 
comprehensive safety analysis, but, reassuringly, the risk 
of vomiting after chloroquine treatment was low and was 
not associated with chloroquine dose.
Current molecular analyses cannot differentiate reliably 
between the three causes of recurrent P vivax parasitaemia: 
recrudescence, relapse, and new infec tions.65 Hence, 
increasing the dose of chloroquine might simply provide a 
prolonged period of chemo prophylaxis, delaying recurrent 
infection rather than preventing recrudescence. Although 
this prolonged chemo- prophylaxis is likely to account for 
some of the reduction in recurrences after a higher 
chloroquine dose, two factors suggest that there is also a 
reduction in the risk of recrudescence. First, regions with 
long relapse periodicity have a low risk of relapse within 
6 weeks of treatment, increasing the likelihood that 
recurrences during this period are attributable to 
recrudescence. A subgroup analysis of patients from long 
relapse periodicity regions showed that a higher dose of 
chloroquine was protective against recurrence even in 
this setting (AHR per 5 mg/kg increase 0·63, 95% CI 
0·42–0·96; p=0·031; appendix p 31). Second, the reduction 
in rate of recurrence associated with chloroquine dose in 
children younger than 5 years did not vary significantly 
over the follow-up period. By contrast, for older patients, 
the hazard ratio decreased after day 21 of follow-up 
compared with earlier. Between days 7 and 21, recurrences 
are more likely to be due to recrudescence, compared with 
Figure 4: Risk of recurrence in patients receiving chloroquine alone or 
chloroquine plus early primaquine in (A) long and (B) short periodicity 
regions
Dashed lines are the 95% CIs. Adjusted for age, sex, and baseline parasitaemia. 
Assumes zero effect from study site. p values are derived from a Cox model.
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relapses or new infections after this time.2,66 Hence, in 
older patients, a higher chloroquine dose might afford 
greater prevention of relapse or new infection between 
days 22 and 42, but have minimal effect on true 
recrudescent infections. Conversely, in younger patients, a 
higher chloroquine dose probably also reduces 
recrudescent infections as a result of relative under-dosing 
of chloroquine despite delivery of the recommended 
chloroquine dose in this age group. Although our study 
design did not allow us to establish conclusively whether 
an increased dose of chloroquine prevents or delays 
parasite recurrence, either response is likely to be of 
substantial clinical benefit to the patient. Both responses 
allow greater time for haematological recovery after the 
initial infection, a reduced risk of cumulative anaemia, 
and thus the potential to reduce associated morbidity and 
mortality.6 However, prospective studies with prolonged 
follow-up are warranted.
The addition of primaquine to chloroquine reduced 
early recurrences before day 42 by 90% compared with 
chloroquine alone; probably in large part as a result of 
prevention of early relapse related to primaquine. 
However, addition of primaquine probably also reduces 
recrudescence through its blood schizontocidal activity, 
potentially in patients with low-grade chloroquine 
resistance. In the current pooled analysis, the reduction 
with chloroquine and primaquine did not vary before 
and after day 21, consistent with a reduction in both 
recrudescences and relapses.
Delayed parasite clearance predicts treatment failure 
in P falciparum malaria.66–68 Similar associations have 
been described in P vivax.5 In the current study, we 
confirm that delayed parasite clearance is associated 
with a higher risk of recurrence at day 28, consistent 
with an association with recrudescence. Although the 
specificity of persistent parasitaemia on day 3 for 
predicting risk of recurrence was 95·8%, the positive 
predictive value was only 23·0% (appendix p 32), 
showing the difficulty in using delayed parasite clearance 
as a measure of an individual’s risk of recurrence. 
However, if parasite clearance was delayed until day 3, 
there was a three-times increased risk of recurrence at 
day 28. This association between delayed parasite 
clearance and recurrence is a potential parameter for 
identifying sites of possible chloroquine resistance, 
since this approach would avoid the confounding effect 
of relapses and reinfections that currently cannot be 
avoided in formal antimalarial efficacy studies.
Our study has several limitations. First, the analysis 
only included about 20% of patients from the clinical 
trials targeted. However, a sensitivity analysis in which 
one study site was removed at a time revealed no apparent 
bias relating to individual study sites that were included, 
and baseline characteristics of patients included had 
similar characteristics to those from all targeted studies 
(appendix p 21). Second, the number of tablets given was 
only available for about 60% of patients, with the 
remainder extrapolated from the protocol and assuming 
complete adherence. However, when the method used to 
calculate dose was included in the multivariable analyses, 
the results remained unchanged (data not shown).
In summary, although the risk of early recurrence of 
P vivax after chloroquine monotherapy is high, it can be 
reduced by a modest increase in the dose of chloroquine, 
particularly in children younger than 5 years, and by the 
additional administration of primaquine. As reports of 
chloroquine treatment failure for P vivax increase, we 
recommend that the dose of chloroquine be increased 
to 30 mg/kg in children younger than 5 years, and 
health-care providers should be encouraged to provide 
adjunctive primaquine radical therapy to reduce the risk 
of both recrudescent and relapsing infections. Alter-
natively, a universal policy of ACT for uncomplicated 
malaria, with additional primaquine for vivax malaria, 
should be considered in regions where there is a high 
risk of recurrent P vivax after chloroquine treatment.
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